Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection

Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection

Abstract The RNA interference (RNAi) drug ARC-520 was shown to be effective in reducing serum hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) in HBeAg-positive patients treated with a single dose of ARC-520 and daily nucleosidic analogue (entecavir)...

Full description

Bibliographic Details
Main Authors: Sarah Kadelka, Harel Dahari, Stanca M. Ciupe
Format: Article
Language:English
Published: Nature Publishing Group 2021-01-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-020-80594-6

Similar Items

Similar Items